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The majority of patients with rheumatoid arthritis (RA) harbours immunoglobulin G 
(IgG) antibodies targeting citrullinated protein antigens (ACPA). Recently, we 
showed that >90% of ACPA-IgG in serum are glycosylated in the variable domain.[1] 
N-linked glycosylation requires a consensus sequence in the protein backbone  
(N-X-S/T, where X is not proline), which is scarce in germline-encoded Ig variable 
region genes.[2, 3] Accordingly, hyperglycosylation of ACPA-IgG requires either 
clonal expansion of B cells expressing B cell receptors (BCR) containing germline-
encoded N-glycosylation sites or generation of de-novo sites through somatic 
hypermutation (SHM).[4] 
Here, we analysed the BCR repertoire of ACPA-expressing B cells to understand the 
molecular basis of this remarkable glycosylation. ACPA-expressing B cells were 
sorted as pools (10 cells per pool) from PBMC of 8 ACPA-positive RA patients.[5] 
ARTISAN PCR-based BCR-sequencing[6] followed by full-length variable region IgG 
transcript analysis revealed high nucleotide mutation rates in 97 unique ACPA-IgG 
heavy chains (HC; mean±SD: 52.86±16.73; figure 1A). 81% of these contained one 
or more N-glycosylation sites.   
To replicate these findings and to acquire additional information on paired heavy and 
light chains (LC), Ig transcripts of 87 single cell-sorted ACPA-IgG clones (6 donors) 
were analysed, again revealing high nucleotide mutation rates in the HC variable 
region (mean±SD: 48.55±16.05; figure 1B). Significantly lower mutation rates were 
observed for 31 single cell-sorted tetanus toxoid (TT)-specific clones (mean±SD: 
25.15±18.92; figure 1B). TT-specific clones contained no N-glycosylation sites, in 
contrast to 79% of HC and 88% of paired HC/LC sequences from the ACPA-IgG 
clones. Additionally, both pool- and single-sorted cell sequence analyses revealed 
similar high nucleotide mutation rates for ACPA-LC (mean±SD: 36.18±15.09 and 
mean±SD: 34.51±16.79, respectively; not shown). Furthermore, 59% of ACPA-LC 
contained one or more N-glycosylation sites compared to 4-5% of healthy control LC. 
Further analyses of HC revealed that all sites in pool/single cell-sorted ACPA-IgG 
clones were introduced by SHM; furthermore, the degree of SHM did not correlate 
with the frequency of sites (figures 1C and 1D). Moreover, no accumulation of N-P-
S/T sites (chosen as reference due to its similarity to N-X-S/T) was observed in 
ACPA-IgG, in contrast to the N-glycosylation tripeptide N-X-S/T. In fact, no N-P-S/T 
sequences were identified by either ACPA-IgG sequencing approach (pool/single 
cell-sorted). Finally, we observed a relative increase  of sites in the complementarity-
determining region (CDR) 1 and a relative absence in CDR3 compared to healthy 
controls (figure 2A). Together, these findings indicate that the remarkable frequency 
of N-glycosylation sites is not the result of random accumulation of mutations but of a 
selective process during maturation of ACPA-expressing B cells. Intriguingly, 
modelling of the spatial positioning of the sites revealed that most sites are located 
on the exterior of the antibody molecule (figures 2B-D). 
In conclusion, we provide the first in-depth analysis of the presence of N-
glycosylation sites in the variable region of ACPA-IgG. The distribution pattern of 
sites across the ACPA-IgG variable domain and the spatial localization of N-
glycosylation sites on the exterior of the molecule suggest that their function in 
selection processes is not primarily related to antigen recognition. Our data favour 
the concept that introduction of N-glycosylation sites generates selective advantages 
which allow ACPA-expressing B cells to escape from classical selection mechanisms 
in germinal centers. This is in contrast to the selection of B cells against recall 
antigens, which is primarily driven by affinity for cognate antigens.[7] In fact, the 
overall low-avidity of secreted polyclonal ACPA-IgG is in line with this hypothesis.[8] 
Possibly, ACPA-IgG variable domain glycans interact with glycan receptors in the 
vicinity of the BCR. These glycans are highly sialylated, suggesting siglecs as 
potential receptors.[2] Thus, these findings and considerations have important 
implications for understanding citrulline-specific immunity in RA. 
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Figure 1. A high degree of somatic hypermutation in ACPA-IgG clones which does 
not correlate with the frequency of N-glycosylation sites. Pool and single cells were 
sorted as described.[5] All independent clones are defined as having identical V, D, J 
genes and CDR3 regions.  
(A) Immunoglobulin heavy variable region (IGHV) mutations in 97 ACPA-IgG clones 
obtained with pool-sequencing (n=8 donors). (B) IGHV mutations in 87 ACPA-IgG 
clones that were positive in CCP2-ELISA compared to 31 TT-IgG clones obtained 
from sequencing of cultured single cells (n=8 and n=3 donors, respectively). P-value 
was calculated using Mann-Whitney U test for unpaired data (**** p < 0.0001). (C) 
Correlation of the number of IGHV mutations with the number of N-glycosylation 
sites of 97 ACPA-IgG clones. Non-parametric Spearman correlation, r = 0.10, p = 
0.32. (D) Correlation of the number of IGHV mutations with the number of N-
glycosylation sites of 87 ACPA-IgG single cell-derived clones. Non-parametric 
Spearman correlation, r = 0.19, p = 0.071. All N-glycosylation sites were introduced 
by SHM. No association between IGHV-gene usage and number of N-glycosylation 
sites was observed using either method.  
 
 
Figure 2. Distribution and spatial localisation of N-glycosylation sites in ACPA-IgG 
clones. (A) Percentage of N-glycosylation sites located in framework (FR) 1, CDR1, 
FR2, CDR2, FR3 and CDR3 regions of IGHV. Distribution of 102 sites in 97 ACPA-
IgG clones obtained with pool-sequencing (left panel, black), 87 sites in 87 ACPA-
IgG clones obtained with sequencing of cultured single cells (right panel, gray), both 
compared to 660 sites in 6724 IGHV sequences from 12 healthy donors (V-region 
matched, red). (B) Structural model of the top view on the antigen binding pocket of 
ACPA-IgG clones. (C) Front view of ACPA-IgG heavy chain structures containing N-
glycosylation sites (asparagine residues colored in green). (D) Front view of ACPA-
IgG light chain structures containing N-glycosylation sites (asparagine residues 
colored in red). All models contain variable regions of 58 ACPA-IgG clones with 
paired heavy and light chain sequences had a confidence score of 100% with a 
sequence identity of 47.7%±7.96 and protein coverage of 98.55%±0.63.  
 
 
 
  
 
